Advertisement

New Therapeutics Targets in Chronic Viral Cardiomyopathy

  • W. Poller
  • H. Fechner
  • U. Kühl
  • M. Pauschinger
  • H. -P. Schultheiss
Conference paper
  • 512 Downloads
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 55)

Abstract

Dilated cardiomyopathy (DCM) is a prevalent heart muscle disease characterized by impaired contractility and dilation of the ventricles. Recent clinical research suggests that cardiotropic viruses are important environmental pathogenic factors in human DCM, which may therefore be considered as a chronic viral cardiomyopathy. All virus-positive DCM patients thus come into the focus of virological research and should be considered for antiviral strategies. Interferon-β therapy has been shown to mediate virus elimination in patients with adenovirus or coxsackievirus persistence.We discuss here several possible new molecular targets for patients infected with cardiotropic viruses in (1) the cellular virus uptake system, (2) virus-induced cellular signaling pathways, and (3) interactions between virus-encoded proteins with important cellular target proteins. The potential of these approaches in the setting of a chronic viral infection is significantly different from that in an acute viral infection. Specific problems encountered in a chronic situation and possible solutions are discussed.

Keywords

Dilate Cardiomyopathy Innate Immune Signaling CVB3 Infection Experimental Autoimmune Myocarditis Lymphocytic Myocarditis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Baboonian C, Davies M, Booth J, McKenna W (1997) Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol 223:31–52PubMedGoogle Scholar
  2. Badorff C, Lee G, lamphear B, et al. (1999) Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5:320–326PubMedCrossRefGoogle Scholar
  3. Bergelson J, Cunningham J, Droguett G, et al (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323PubMedCrossRefGoogle Scholar
  4. Bhuyan PK, Kariko K, Capodici J, et al (2004) Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. J Virol 78:10276–10281PubMedCrossRefGoogle Scholar
  5. Bowles N, Richardson P, Olsen E, Archard L (1986) Detection of coxsackie-B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1:1120–1123PubMedCrossRefGoogle Scholar
  6. Chien K (2003) Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin Invest 111:175–178PubMedCrossRefGoogle Scholar
  7. Dave RS, Pomerantz RJ (2004) Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J Virol 78:13687–13696PubMedCrossRefGoogle Scholar
  8. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN (2004) Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110:3540–3543PubMedCrossRefGoogle Scholar
  9. Dörner A, Xiong D, Couch K, Yajima T, Knowlton K (2004) Alternatively spliced soluble Coxsackie-adenovirus receptors inhibit Coxsackievirus infection. J Biol Chem 279:18497–18503PubMedCrossRefGoogle Scholar
  10. Fechner H, Noutsias M, Tschoepe C, et al (2003) Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling — identification of a cell-cell contact dependent regulatory mechanism. Circulation 107:876–882PubMedCrossRefGoogle Scholar
  11. Franz W, Muller O, Katus H (2001) Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358:1627–1637PubMedCrossRefGoogle Scholar
  12. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virologic and immunologic profile of responders versus non-responders. Circulation 107:857–863PubMedCrossRefGoogle Scholar
  13. Gaggar A, Shayakhmetov D, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408–1412PubMedCrossRefGoogle Scholar
  14. Gao X, Wang H, Sairenji T (2004) Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. J Virol 78:11798–11806PubMedCrossRefGoogle Scholar
  15. Grimm D, Pandey K, Kay MA (2005) Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol 392:381–405PubMedGoogle Scholar
  16. Hertzog P, O’Neill L, Hamilton J (2003) The interferon in TLR signaling: more than just antiviral. Trends Immunol 24:534–539PubMedCrossRefGoogle Scholar
  17. Kameoka M, Nukuzuma S, Itaya A, et al. (2004) RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol 78:8931–8934PubMedCrossRefGoogle Scholar
  18. Kühl U, Pauschinger M, Schwimmbeck P, et al (2003a) Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793–2798PubMedCrossRefGoogle Scholar
  19. Kühl U, Pauschinger M, Bock T, et al. (2003b) Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108:945–950PubMedCrossRefGoogle Scholar
  20. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111:887–893PubMedCrossRefGoogle Scholar
  21. Li G, Li XP, Peng Y, Liu X, Li XH (2004) Effect of inhibition of EBV-encoded latent membrane protein-1 by small interfering RNA on EBV-positive nasopharyngeal carcinoma cell growth. Di Yi Jun Yi Da Xue Xue Bao 24:241–246PubMedGoogle Scholar
  22. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F, Wen WH, Kozieradzki I, Bachmaier K, Straus D, Mak TW, Penninger JM (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6:429–434PubMedCrossRefGoogle Scholar
  23. Lu A, Zhang H, Zhang X, et al. (2004) Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. Virology 324:84–89PubMedCrossRefGoogle Scholar
  24. Matsumori A, Matoba Y, Sasayama S (1995) Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92:2519–2525PubMedGoogle Scholar
  25. Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S (2000) Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80:1137–1142PubMedGoogle Scholar
  26. Michel U, Malik I, Ebert S, Bahr M, Kugler S (2005) Long-term in vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary neurons. Biochem Biophys Res Commun 326:307–312PubMedCrossRefGoogle Scholar
  27. Murry C, Jerome K, Reichenbach D (2001) Fatal parvovirus myocarditis in a 5-year-old girl. Hum Pathol 32:342–345PubMedCrossRefGoogle Scholar
  28. Nigro G, Bastianon V, Colloridi V, et al (2000) Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Microbiol Infect 31:65–69Google Scholar
  29. Noutsias M, Fechner H, Jonge Hd, et al (2001) Human coxsackie-adenovirusreceptor is co-localized with integrins avb3 and avb5 on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy — implications for cardiotropic viral infections. Circulation 104:275–280PubMedGoogle Scholar
  30. Opavsky M, Martino T, Rabinovitch M, et al (2002) Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 109:1561–1569PubMedCrossRefGoogle Scholar
  31. Pauschinger M, Bowles N, Fuentes-Garcia J, et al. (1999a) Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99:1348–1354PubMedGoogle Scholar
  32. Pauschinger M, Doerner A, Kuehl U, et al (1999b) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99:889–895PubMedGoogle Scholar
  33. Ping YH, Chu CY, Cao H, Jacque JM, Stevenson M, Rana TM (2004) Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. J Acquir Immune Defic Syndr Hum Retrovirol 1:46Google Scholar
  34. Pinkenburg O, Platz J, Beisswenger C, Vogelmeier C, Bals R (2004) Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods 120:119–122PubMedCrossRefGoogle Scholar
  35. Poller W, Kuhl U, Tschoepe C, Pauschinger M, Fechner H, Schultheiss HP (2005) Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy. J Molec Med [Epub head of print 2 June 2005]Google Scholar
  36. Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A (2001) Fatal myocarditis associated with acute parvovirus B19 and herpesvirus 6 coinfection. J Clin Microbiol 39:4585–4587PubMedCrossRefGoogle Scholar
  37. Schubert S, Grunert H-P, Zeichhardt H, Werk D, Erdmann V, Kurreck J (2005) Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J Mol Biol 346:457–465PubMedCrossRefGoogle Scholar
  38. Stevenson M (2004) Therapeutic potential of RNA interference. N Engl J Med 351:1772–1777PubMedCrossRefGoogle Scholar
  39. Takigawa Y, Nagano-Fujii M, Deng L, et al (2004) Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol 48:591–598PubMedGoogle Scholar
  40. Ulevitch R (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4:512–520PubMedCrossRefGoogle Scholar
  41. Wang Z, Ren L, Zhao X, et al. (2004) Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol 78:7523–7527PubMedCrossRefGoogle Scholar
  42. Why HJ, Meany BT, Richardson PJ, et al (1994) Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 89:2582–2589PubMedGoogle Scholar
  43. Wiebusch L, Truss M, Hagemeier C (2004) Inhibition of human cytomegalovirus replication by small interfering RNAs. J Gen Virol 85:179–184PubMedCrossRefGoogle Scholar
  44. Xia H, Mao Q, Eliason SL, et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816–820PubMedCrossRefGoogle Scholar
  45. Xiong D, Lee G-H, Badorff C, et al. (2002) Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat Med 8:782–877Google Scholar
  46. Yanagawa B, Spiller OB, Choy J, et al. (2003) Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 83:75–85PubMedGoogle Scholar
  47. Yanagawa B, Spiller OB, Proctor DG, et al (2004) Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis 189:1431–1439PubMedCrossRefGoogle Scholar
  48. Yokoseki O, Suzuki J, Kitabayashi H, et al (2001) cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 89:899–906PubMedGoogle Scholar
  49. Yoon JS, Kim SH, Shin MC, et al. (2004) Inhibition of herpesvirus-6B RNA replication by short interference RNAs. J Biochem Mol Biol 37:383–385PubMedGoogle Scholar
  50. Zhang XN, Xiong W, Wang JD, Hu YW, Xiang L, Yuan ZH (2004) siRNAmediated inhibition of HBV replication and expression. World J Gastroenterol 10:2967–2971PubMedGoogle Scholar
  51. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ (2004) Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 11:1703–1712PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • W. Poller
    • 1
  • H. Fechner
    • 1
  • U. Kühl
    • 1
  • M. Pauschinger
    • 1
  • H. -P. Schultheiss
    • 1
  1. 1.Department of Cardiology and Pneumology, Campus-Benjamin FranklinCharité University Medicine BerlinBerlinGermany

Personalised recommendations